

## ASX ANNOUNCEMENT MARKET RELEASE

1 August 2022

### Artrya Strengthens Board with US-based Director

---

#### Key Points:

- Dr Jacque Sokolov appointed to the Artrya Limited Board as non-executive director
  - Dr Sokolov is a recognised leader in the US healthcare care sector having advised companies across the US and government entities, including the White House under four presidents, Senate and House committees
  - Dr Sokolov is Chairman and President, Artrya USA Inc. and is Chairman of the Artrya Clinical Advisory Board
- 

Perth, Western Australia., (1 August 2022) – Australian medical technology company, Artrya Limited (ASX: AYA) (Artrya or the Company) is announcing the appointment of Dr Jacque Sokolov to the Artrya Limited Board as a non-executive director effective immediately.

Artrya Chair, Bernie Ridgeway, said he is delighted to welcome Dr Jacque Sokolov to the Board and that today's announcement represents a key milestone.

"Dr Sokolov's appointment is strongly aligned with Artrya's growth strategy as an AI medical technology company. There were always plans to expand the Board and this is the right time. Dr Sokolov's remarkable breadth of experience across all aspects of the US healthcare industry, in particular healthcare delivery, biotechnology and regulatory clearance, strengthens the Board as the Company continues to develop market entry strategies, clinical research and go to market plans".

"Dr Sokolov will be an important contributor as we execute our growth priorities and pursue regulatory clearance. As a formally trained academic cardiologist with proven strategic leadership, having served on multiple US public, private and not-for-profit healthcare boards, he brings a unique, dynamic and significant insight," Mr Ridgeway said.

Commenting on his appointment Dr Sokolov said he is pleased to be contributing to Artrya's strategic evolution.

"This is such an important opportunity – to support diagnosing clinicians in both emergency and primary care and, moreover, help to save the lives of those at risk of adverse cardiac events," Dr Sokolov said.

Artrya Salix supports clinicians both in emergency and out-patient care by helping to rule out (or in) patients with coronary artery disease within minutes. This advanced technology offers healthcare systems an

enterprise-level solution that may deter the need for additional or invasive testing, reduce excessive patient admission and encourage appropriate patient treatment to be offered sooner.

#### **About Dr Sokolov**

Dr. Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company. His company has worked with more than 100 healthcare organisations across multiple US healthcare sectors to develop physician-driven, value-focused solutions in rapidly evolving markets.

Dr. Sokolov currently serves on multiple public, private and not-for-profit healthcare boards. He is especially focused on leading technology involving advanced digital health companies such as GlobalMed and next-generation genetic-based companies such as Calviri (mRNA diagnostics/products) and Lucid Diagnostics (DNA diagnostics-LUCD: NASDAQ).

Dr. Sokolov received his BA and MD Degrees from the University of Southern California and completed his internal medicine residency at the Mayo Graduate School of Medicine followed by his fellowship in cardiovascular diseases/nuclear cardiology from the University of Texas-Southwestern Medical School.

Dr Sokolov was appointed Artrya Clinical Advisory Board Chair in January 2022 and Chairman and President of Artrya USA Inc. in March 2022.

*This announcement was approved by the Artrya Board.*

---

**For further information please contact:**

**Investor Enquiries:**

John Barrington  
Artrya Limited  
+61 419 850 502  
investors@artrya.com

**Media Enquiries:**

Brett McCarthy  
Artrya Limited  
+61 401 704 451  
brett.mccarthy@artrya.com

#### **About Artrya**

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information: [www.artrya.com](http://www.artrya.com)